Augmentation strategies in patients with refractory depression

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Treatment-resistant depression (TRD) poses a significant clinical challenge.
• Accurate diagnosis is essential to differentiate true resistance from suboptimal prior treatment (dose, duration, compliance).
• Potential confounding factors include psychiatric comorbidities, depressive subtypes, and medical etiologies.

Purpose of the Study:

• To outline key considerations in evaluating and managing treatment-resistant depression.
• To differentiate true antidepressant resistance from inadequate past treatment.
• To review evidence-based augmentation strategies for TRD.

Main Methods:

• Review of diagnostic criteria and management principles for TRD.
• Analysis of augmentation strategies for antidepressant therapy.
• Evaluation of evidence for adjunctive treatments including lithium and thyroid hormone.

Main Results:

• Distinguishing true TRD requires careful reassessment of diagnosis and prior treatment adequacy.
• Augmentation of tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs) with thyroid hormone (T3) or lithium is supported by open and controlled trials.
• Emerging data suggest potential efficacy for other strategies like higher-dose treatments, specific agents (venlafaxine), combined therapies, electroconvulsive therapy (ECT), and transcranial magnetic stimulation (TMS).

Conclusions:

• Effective management of TRD necessitates a thorough diagnostic evaluation and patient-specific treatment planning.
• Augmentation with thyroid hormone or lithium represents established strategies for TRD.
• Further research is warranted to confirm the efficacy of other emerging treatment modalities for TRD.